|
|
|
| Curative Efficacy of Permetazole Sodium combined with Cisplatin in treatment of Advanced Lung Adenocarcinoma and its Effects on Serum cyfra21-1 CA125 and CEA |
| LUO Juan, LI Rong, HUANG Chunmei, et al |
| Meishan People's Hospital, Sichuan Meishan 620010, China |
|
|
|
|
Abstract Objective: To study curative efficacy of permetazole sodium combined with cisplatin in treatment of advanced lung adenocarcinoma and its effectson serum cytokine fragment antigen 21-1 (cyfra21-1), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA). Methods: 90 patients with advanced lung adenocarcinoma from May 2014 to May 2017 for research, they were randomly divided into observation group (n=50) and control group (n=40). The observation group was treated with the combination of permetazole and cisplatin. The control group was treated with paclitaxel combined with cisplatin. Clinical efficacy, CEA, CA125, cyfra21-1, neuron-specific enolase (NSE) and adverse reactions were compared between the two groups. Results: After treatment, the effective rate of the observation group was 72.00% after treatment, which was significantly higher than 42.50% of the control group (P<0.05). Before treatment, there was no significant difference in the serum cyfra21-1, CA125 and CEA levels between the two groups. After treatment, the serum cyfra21-1, CA125 and CEA levels of both groups decreased (P<0.05). The serum cyfra21-1, CA125 and CEA levels of the observation group were all lower than those of the control group (P<0.05). Before treatment, there was no significant difference in serum NSE level between the two groups. After treatment, serum NSE level decreased (P<0.05). The serum NSE level of the observation group was lower than that of the control group (P<0.05). During the treatment, the adverse reaction rate of the observation group was significantly lower than that of the control group (P<0.05). Conclusion: Patients with advanced lung adenocarcinoma treated by pmetraxer disodium combined with cisplatin have higher efficacy, which can effectively improve the levels of cyfra21-1, CA125 and CEA in serum of patients with less adverse reactions, and the patients are basically tolerable and worthy of popularization and application.
|
|
|
|
|
|
[1] 程晓叁,翁洁,文芳,等.多西他赛联合阿帕替尼二线治疗晚期肺腺癌[J].中国新药与临床杂志,2018,37(4):229~232.
[2] Zhang Q, Ke E, Niu F, et al. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma[J]. Oncotarget, 2017, 8(3):4994~5002.
[3] Taiji K, Kazue Y, Kenichi K, et al. Achievement of cure with gefitinib in advanced lung adenocarcinoma harboring an activating EGFR mutation: a case report:[J]. Case Reports in Oncology, 2016, 9(3):565~567.
[4] 周毅,周健,张莹,等.培美曲塞联合奈达铂治疗晚期肺腺癌临床疗效及其安全性观察[J].第三军医大学学报,2018,40(13):1236~1241.
[5] 钟文昭,董嵩,李磊,等.国际肺癌研究协会/美国胸科学会/欧洲呼吸学会肺腺癌的国际多学科分类[J].循证医学,2011,11(4):193~225.
[6] Gottfried M, Bennouna J, Bondarenko I, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-Lung 1 study[J]. Targeted Oncology, 2017, 12(4):475~485.
[7] 张朝巍.贝伐单抗与培美曲塞、顺铂联合治疗晚期肺腺癌的临床效果及对VEGF的影响[J].山东医药,2017,57(25):90~92.
[8] 范群,伍小平,戴文香,等.培美曲塞与铂类化疗药联合使用对晚期肺腺癌患者治疗有效性与安全性研究[J].东南大学学报(医学版),2017,36(5):723~728.
[9] 徐经芳.培美曲塞联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究[J].现代肿瘤医学,2014,22(7):1572~1574.
[10] 段新春,崔永,龚民,等.手术前后血清CEA和CYFRA21-1水平的变化有助于预测非小细胞肺癌患者的预后[J].中国肺癌杂志,2015,18(6):358~364. |
|
|
|
2019, Vol. 25 
